Informed Consent form

Patient information sheet (PIS) and Informed Consent form (ICF) document

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial

Anil Tibdewal, JP Agarwal, Kumar Prabhash, Naveen Mummudi, Vanita Noronha, Amit Joshi, Vijay Patil, Nilendu Purandare, Amit Janu, Abhishek Mahajan, Rajiv Kumar, Tapas Dora and Sadhana Kannan.

1. Information to participate in the research project

This document explains the study for which you are being considered as participant. Before consenting for the study, it is important that you read and understand the research questions, additional benefits, possible risks and study related procedures. Please feel free to approach the study team for clarifying any doubts for asking any question arising in relation to the study being proposed. You are also free to discuss with your family members of and before deciding about study participation. If you decide to participate in the study then you will have to sign the consent form. By signing the form, you are stating that you understand the information about the study, agree to the treatment procedure and willing to take part in the study.

Radiotherapy is a standard treatment for metastatic non-small cell lung cancer. In metastatic setting, radiotherapy is general given for palliative setting. However, even in metastatic setting, if the patients have limited number of metastatic sites usually less than 5 then this condition is called Oligometastases. In oligometastatic non-small cell lung cancer, patients after completion of systemic therapy has no evidence of progression then can be treated with radical radiotherapy to all the oligometastatic sites with curative intent. This therapy has resulted in better outcomes than maintenance systemic therapy alone (observation or more chemotherapy). In this study, we want to study the effects of local consolidative radiation therapy (LCRT) to all sites of oligometastatic disease in addition to standard maintenance therapy for its beneficial effects in improving the overall survival.

2. Nature and purpose of this study

Version No. 1.0, 04/01/2020

All consecutive oligometastatic NSCLC patients with 1-5 sites of metastases initially treated with 4-6 cycles of systemic therapy will be screened for this study. Patients without evidence of progressive disease will be eligible for this study. The study will involve 300 patients. Patients willing for participation will be asked to sign the written informed consent form. Subsequently, these patients will be randomly allocated to receive maintenance therapy in the form of observation or further chemotherapy OR local consolidative radiation therapy to all initial sites of Oligometastases and standard maintenance therapy i.e half of the patients in the trial will continue to receive TKI alone and half will receive TKI + local consolidative Radiation therapy. The study team with the help of computers will do the treatment allocation after checking pertinent details regarding your disease condition. You have equal chance of receiving RT on not receiving it. In every other aspect, the treatment will be the same. If you are allocated to receive radiation, it will be planned within 2- 4 weeks after you agreed to participate in this study.

3. Study Methodology

Radiotherapy for metastatic non-small cell lung cancer is a relatively simple form of treatment delivered using beams of high-energy x ray. The planning process involved taking some measurement and a computed tomography CT scan in a position necessary for the treated sites and patient comfort. The planning session usually take 20 to 40 minutes. You will receive radiation to all the metastatic sites and primary disease. During treatment, you will be set up in the same position as you were during the planning session. Radiation is usually delivered daily Monday to Friday as outpatient. Each treatment session will take about 10 to 15 minutes depending upon the sites being treated.

All participating patients will be followed up for at least five years. The first follow-up will be done at 3 months post radiotherapy completion and then subsequently you will be seen at 3 monthly interval up to 2 years in the hospital clinic for a routine examination there after you will be reviewed every six monthly for 5 years or more.

Another aspect that we would like to study the impact of local consolidative radiation treatment on your quality of life. For assessing this, you would be requested to fill in questionnaire that contains various items related to Physical, emotional and social wellbeing. You will be asked to fill this form before start of treatment and at regular intervals thereafter. Each questionnaire will take about 30 minutes to complete apart.

4. Biological and Radiomics substudy

Version No. 1.0, 04/01/2020

Apart from the main study, we would like to do further research on your blood sample for circulating tumor cells & molecular studies and your radiologic images for Radiomics analysis. With your permission, we would like to preserve some parts of your cancerous tissue embedded in paraffin blocks at the pathological laboratory of Tata Memorial Hospital for 10 years. Your tissue would be stored in a way that it would not be identifiable and no one would be informed about specific findings related to you. Five ml of blood sample will be collected at baseline and at 3,6 and 12 months for the biological part of the study. Blood sample will be processed at a partner research laboratory in Pune. Other scientists or doctors may want to use this material to improve diagnosis and treatment of cancer after getting approval from the institutional ethics committee. If you agree to donate your biological material or let use of radiologic images for future studies, kindly give a separate consent for the same in addition to the main study. However, you are free to participate in the main study even if you decide not to donate the biological material.

5. Risks and side effects

Like any other treatment, RT caused side effects depending upon the area of the body being treated. The short-term general side effect in the form of redness, pigmentation or itching of the skin in the irradiated area, which is expected to subside within a month of completion of treatment. For example, if you are being treated for lung mass, RT may cause inflammation of the lung causing dry cough, shortness of breath and chest wall pain. However, these side effects are minimal by careful planning and using modern RT techniques. For further questions on side effects relating to specific sites, please consult the study team doctors. For any unforeseen radiation induced complications, patients will be managed at Tata Memorial hospital and treatment cost will be borne by the study team.

6. Costs

The study protocol will cover the cost of MRI Brain and you do not have to pay for it. You are not expected to pay for the radiation if you are allocated to receive RT. However, you will have to bear the cost of systemic therapy drugs, which you were previously taking before participating in this study and routine tests/procedure considered standard for staging, treatment and follow up. Thus, the cost of your standard treatment as well as the cost of managing any complication directly or indirectly attributable to this standard treatment would have to be borne by you or your caregivers.

Version No. 1.0, 04/01/2020

7. Benefits

There are no direct monetary or financial benefits for participation in this study. We do not anticipate that any new information gained during the course of the study will benefit you directly. Many of the most effective treatments used today are the results of clinical trials done in the past. However, irrespective of your participation in the trial you will receive high standards of care. Moreover, close contact with the study team will be beneficial. Information from this study will improve our knowledge of treating non-small cell lung cancer with limited metastatic disease especially the benefits of RT.

8. Confidentiality

All information obtained during the study will be held in strict confidence. You will be identified with study number only. No names or identifying information will be used in images for any publication or presentation. Only the doctors and associates working on this study will have access to your medical charts in order to collect information on your treatment and the outcomes thereof. They will require access to your medical charts during your treatment and up to 5 years following your treatment. If you withdraw early from the study, no further collection of information from your medical charts will take place. However, information collected up to the point of withdrawal would still be used. The information in the study record will be kept confidential and the clinical chart will be kept in the Clinical Research secretariat (CRS) at TMC. Data will be stored securely and will be made available only to persons conducting the study. No reference will be made in oral or written reports, which would link you to the study.

9. Compensation

In the event of an injury occurring to the clinical trial subject, related to the intervention arm, such subject should be provided free medical management as long as required. In the event of a study related injury and death, compensation will be provided as per the institutional policy.

10. Reimbursement

You will not receive any reimbursement for the routine tests/procedures and the standard treatment that is being offered to you in the study.

Version No. 1.0, 04/01/2020

11. Contact

If you have any questions regarding the study or the procedures at any time, you may contact the Principal investigator on this study, Dr. Anil Tibdewal, Room number 306 Homi Bhabha Block 3rd floor, Radiation Oncology OPD (Tel 91-22-2417 7000, Extension 6315 at Tata Memorial Hospital or Room no 1130 (Tel 24177030) at Tata Memorial Hospital between 9:30 a.m. to 5:30 p.m. In case you have any question regarding your rights as a participant or wish to clarify certain issues from a non-investigator on this study, you can contact Dr. Umesh Mahantshetty or Dr. Girish Chinnaswamy, Member Secretary IEC, Tata Memorial Hospital, Parel, Mumbai on 91-22-24177262.

12. Participation

Your participation in this study is completely voluntary. You are free to refuse participation, or to leave the study at any time. You will not be penalized or lose any benefit to which you are otherwise entitled. If you withdraw from the study prior to its completion you will receive the usual standard of care for the disease and your non- participation will not have any adverse effect on your subsequent medical treatment or relationship with the treating physician. Additionally, we may discontinue the study at any time without your consent for safety or Administrative reasons.

Version No. 1.0, 04/01/2020

Informed Consent form (Main study)

Study Title: Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial

Study number: _____

Subject's Name: _____

Subject's Initials: _____

Date of birth/Age: _____

1. I confirm that I have read and understood the information sheet dated _____ for the above study and have had the opportunity to ask questions.
2. I understand that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.
3. I understand that the sponsor of the research study, others working on the sponsor's behalf, IEC and the regulatory authorities will not need my permission to look at my health records both in respect of the current study and any further research that may be conducted in relation to it, even if I withdraw form this trial. I agree to this access. However, I understand that my identity will not be revealed in any information released to third parties or published.
4. I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s).
5. I agree to take part in the above study.

I have read the above information and agreed to participate in this study. I have received a copy of this form.

Version No. 1.0, 04/01/2020

Participant's name (print)	
Participant's signature or thumb impression and date	
Address: Qualification: Occupation: Student/Self-employed/service/Housewife/others (please tick as appropriate) and attach supporting documentation Annual Income of the subject (please attach supporting documentation)	
Phone Nos:	
Legal acceptable representative name	
Legal acceptable representative signature or thumb impression and date	
Address (Capital letters) Phone numbers	
Impartial witness's name	
Impartial witness's signature and date	
Address (capital letters) Phone numbers	
Name of PI or Co-PI/Co-I	
PI or Co-PI/Co-I signature and date	

Version No. 1.0, 04/01/2020

Informed Consent form

Study Title: Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial

I hereby freely give my consent to take part in the BIOLOGICAL and Radiomics sub study for which I wish to donate the following materials/agree to let use of my radiology scan images.

Blood ☐

Tumor tissue ☐

Radiology Images ☐

Participant's name (print)	
Participant's signature and date	
Phone Nos:	
Legal acceptable representative name	
Legal acceptable representative signature and date	
Address (Capital letters) Phone numbers	
Impartial witness's name	
Impartial witness's signature and date	
Address (capital letters) Phone numbers	
Name of PI or Co-PI/Co-I	

Version No. 1.0, 04/01/2020

PI or Co-PI/Co-I signature and date	

Version No. 1.0, 04/01/2020